Compare BIIB & NWS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIIB | NWS |
|---|---|---|
| Founded | 1978 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Newspapers/Magazines |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 16.2B |
| IPO Year | 1991 | N/A |
| Metric | BIIB | NWS |
|---|---|---|
| Price | $181.52 | $29.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 7 |
| Target Price | ★ $176.48 | $37.95 |
| AVG Volume (30 Days) | ★ 1.9M | 754.5K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 0.68% |
| EPS Growth | N/A | ★ 230.83 |
| EPS | ★ 10.97 | 2.06 |
| Revenue | ★ $10,065,900,000.00 | $8,500,000,000.00 |
| Revenue This Year | $3.61 | $5.10 |
| Revenue Next Year | N/A | $3.24 |
| P/E Ratio | $16.52 | ★ $12.98 |
| Revenue Growth | ★ 4.77 | 2.20 |
| 52 Week Low | $110.04 | $26.25 |
| 52 Week High | $185.17 | $35.58 |
| Indicator | BIIB | NWS |
|---|---|---|
| Relative Strength Index (RSI) | 72.92 | 51.01 |
| Support Level | $174.53 | $28.69 |
| Resistance Level | $182.94 | $29.59 |
| Average True Range (ATR) | 5.22 | 0.55 |
| MACD | 0.25 | 0.12 |
| Stochastic Oscillator | 83.54 | 89.67 |
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
News Corporation is a diversified media conglomerate with large presence in the US, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. Its 61%-owned REA Group is the dominant property listings platform in Australia. In addition, it owns Harper Collins, one of the largest book publishers in the world, and has a sizable US digital property advertising business, Move. The 65% interest in Foxtel, the Australian pay-TV and streaming provider, was sold in April 2025. The sale to global sports streaming platform, DAZN, was struck at more than 7 times Foxtel's EBITDA.